Logo for Oncopeptides

Oncopeptides Investor Relations Material

Latest events

Logo for Oncopeptides

Q1 2024

Oncopeptides
Logo for Oncopeptides

Q1 2024

30 May, 2024
Logo for Oncopeptides

Investor Update

13 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Oncopeptides

Access all reports
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden